Please assess the completion status of the following clinical trial:

Trial Title: Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects~* Women: non-pregnant, non-lactating; if of childbearing potential, on specified contraception measures during the study period~* Men: using barrier contraception measures during the study period~Exclusion Criteria:~* Health conditions~* Taking prescription and non-prescription drugs (exceptions: acetaminophen, vitamins, hormonal birth control)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 - 3 mg UV-4B (Type: EXPERIMENTAL): Subjects receiving UV-4B 3 mg oral solution or placebo
- Cohort 2 - 10 mg UV-4B (Type: EXPERIMENTAL): Subjects receiving UV-4B 10 mg oral solution or placebo
- Cohort 3- 30 mg UV-4B (Type: EXPERIMENTAL): Subjects receiving UV-4B 30 mg oral solution or placebo
- Cohort 4 - 90 mg UV-4B (Type: EXPERIMENTAL): Subjects receiving UV-4B 90 mg oral solution or placebo
- Cohort 5 - 180 mg UV-4B (Type: EXPERIMENTAL): Subjects receiving UV-4B 180 mg oral solution or placebo
- Cohort 6 - 360 mg UV-4B (Type: EXPERIMENTAL): Subjects receiving UV-4B 360 mg oral solution or placebo
- Cohort 7 - 720 mg UV-4B (Type: EXPERIMENTAL): Subjects receiving UV-4B 720 mg oral solution or placebo
- Cohort 8 - 1000 mg UV-4B (Type: EXPERIMENTAL): Subjects receiving UV-4B 1000 mg oral solution or placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).